Cas 873857-62-6 Rna Synthesis Inhibitors Antibiotics Fidaxomicin
Cas 873857-62-6 Rna Synthesis Inhibitors Antibiotics Fidaxomicin
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:Fidaxomicin |
Purity:98% min |
|
CAS NO:873857-62-6 |
Solubility:DMSO33 mg/mL (31.19 mM) |
|
Molecular Formula:C52H74Cl2O18 |
Package:Package according to customer requirements |
|
Molecular Weight:1058.040 |
Storage:Store at -20℃ |
Quality control
COA
Remarks
Fidaxomicin is the first in a new class of narrow spectrum macrocyclic antibiotic drugs. It is a fermentation product obtained from the actinomycete Dactylosporangium aurantiacum subspecies hamdenesis. Fidaxomicin is non-systemic, meaning it is minimally absorbed into the bloodstream, it is bactericidal, and it has demonstrated selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora. The maintenance of normal physiological conditions in the colon can reduce the probability of Clostridium difficile infection recurrence.
Related Prodcuts:
Marbofloxacin; CP-466722; TTP 22; D-64131; M344; CHIR-124; Reversine; Pralatrexate; XL228; VE-822; RI-1; SRPIN340; XL888; Rigosertib; APY29; NMS-873; PF-03758309; Telatinib
References
-
[1] Steeghs N, et al. Clin Cancer Res, 2008, 14(11), 3470-3476.
-
[2] Strumberg D, et al. Br J Cancer, 2008, 99(10), 1579-1585.
-
[3] Eskens FA, et al. J Clin
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.